Consolidated Portfolio Review Corp Astrazeneca PLC Transaction History
Consolidated Portfolio Review Corp
- $632 Billion
- Q4 2024
A detailed history of Consolidated Portfolio Review Corp transactions in Astrazeneca PLC stock. As of the latest transaction made, Consolidated Portfolio Review Corp holds 5,234 shares of AZN stock, worth $376,795. This represents 0.05% of its overall portfolio holdings.
Number of Shares
5,234Holding current value
$376,795% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding AZN
# of Institutions
1,350Shares Held
477MCall Options Held
5.39MPut Options Held
3.75M-
Price T Rowe Associates Inc Baltimore, MD62.9MShares$4.53 Billion0.56% of portfolio
-
Primecap Management CO Pasadena, CA42MShares$3.02 Billion2.45% of portfolio
-
Wellington Management Group LLP Boston, MA37.2MShares$2.68 Billion0.52% of portfolio
-
Capital International Investors Los Angeles, CA36.8MShares$2.65 Billion0.57% of portfolio
-
Franklin Resources Inc San Mateo, CA19.1MShares$1.38 Billion0.45% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $223B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...